Literature DB >> 21132519

Acrylic acid-methyl methacrylate (2.5:7.5/2:8) enteric copolymer for colon targeted drug delivery.

Saurabh Vijay1, O P Sati, Dipak K Majumdar.   

Abstract

Enteric copolymers of acrylic acid and methyl methacrylate (2.5:7.5 and 2:8) were prepared using tetrahydrofuran as solvent and AIBN as free radical initiator for colon targeting. FTIR and (1)H NMR spectra of the copolymers showed absence of vinyl bond/protons present in the monomers suggesting successful polymerization. Flurbiprofen sodium microspheres (M1 and M2) made with the copolymers, by oil/oil solvent evaporation, were spherical, anionic (zeta potential -57.8 and -53.7 mV) and contained 5.47 and 5.89% drug. FTIR spectrum of microspheres showed peaks for aromatic C = C stretching and substituted benzene ring, indicating entrapment of flurbiprofen. PXRD revealed crystalline structure of flurbiprofen while copolymer and microspheres were amorphous. DSC thermograms showed a sharp melting endotherm of flurbiprofen sodium at 129.26°C against broad endotherms of copolymers and microspheres. The microspheres released 43 and 36% drug at pH 6.8 in 2 h and 99 and 96% at pH 7.4 in next 3-4 h.The microspheres did not adhere on gastric-mucosa at pH 1.2 but showed mucoadhesion time of 18 min and 9 min on intestinal mucosa at pH 6.8. Thus, the microspheres on oral administration, would release the drug in colon, suggesting the potential of the hemocompatible copolymers for pH dependent colon targeted drug delivery system.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21132519     DOI: 10.1007/s10856-010-4192-4

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  19 in total

Review 1.  Microbially triggered drug delivery to the colon.

Authors:  V R Sinha; Rachna Kumria
Journal:  Eur J Pharm Sci       Date:  2003-01       Impact factor: 4.384

Review 2.  Mechanisms of NSAID-induced gastroenteropathy.

Authors:  A H Price; M Fletcher
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 3.  Multiparticulate formulation approach to colon specific drug delivery: current perspectives.

Authors:  Laila Fatima Ali Asghar; Sajeev Chandran
Journal:  J Pharm Pharm Sci       Date:  2006       Impact factor: 2.327

4.  Physicomechanical properties of naproxen-loaded microparticles prepared from Eudragit l100.

Authors:  M Maghsoodi
Journal:  AAPS PharmSciTech       Date:  2009-01-31       Impact factor: 3.246

5.  Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges.

Authors:  Mine Orlu; Erdal Cevher; Ahmet Araman
Journal:  Int J Pharm       Date:  2006-03-29       Impact factor: 5.875

6.  Antiproliferative effects of the enantiomers of flurbiprofen.

Authors:  J D McCracken; W J Wechter; Y Liu; R L Chase; D Kantoci; E D Murray; D D Quiggle; Y Mineyama
Journal:  J Clin Pharmacol       Date:  1996-06       Impact factor: 3.126

7.  Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region.

Authors:  M Rodríguez; J L Vila-Jato; D Torres
Journal:  J Control Release       Date:  1998-10-30       Impact factor: 9.776

8.  Microsphere design for the colonic delivery of 5-fluorouracil.

Authors:  Alf Lamprecht; Hiromitsu Yamamoto; Hirofumi Takeuchi; Yoshiaki Kawashima
Journal:  J Control Release       Date:  2003-07-31       Impact factor: 9.776

9.  15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is up-regulated by flurbiprofen and other non-steroidal anti-inflammatory drugs in human colon cancer HT29 cells.

Authors:  Xiuling Chi; Brittany Morgan Freeman; Min Tong; Yuhua Zhao; Hsin-Hsiung Tai
Journal:  Arch Biochem Biophys       Date:  2009-06-06       Impact factor: 4.013

10.  R-flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75(NTR) induction.

Authors:  Haifeng Jin; Zhipeng Wang; Lili Liu; Liucun Gao; Li Sun; Xiaohua Li; Hongxi Zhao; Yanglin Pan; Hai Shi; Na Liu; Liu Hong; Jie Liang; Qiong Wu; Zhiping Yang; Kaichun Wu; Daiming Fan
Journal:  Mol Pharm       Date:  2010-02-01       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.